|2.||Hodgkin Disease (Hodgkin's Disease)
|3.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
|1.||Rothman, Nathaniel: 52 articles (10/2015 - 11/2002)|
|2.||Witzig, Thomas E: 52 articles (09/2015 - 01/2002)|
|3.||Leonard, John P: 44 articles (11/2015 - 02/2002)|
|4.||Vose, Julie M: 44 articles (10/2015 - 01/2002)|
|5.||Goldenberg, David M: 44 articles (06/2015 - 01/2003)|
|6.||Cerhan, James R: 44 articles (02/2015 - 03/2002)|
|7.||Lan, Qing: 35 articles (10/2015 - 01/2006)|
|8.||Friedberg, Jonathan W: 33 articles (10/2015 - 01/2002)|
|9.||Gordon, Leo I: 33 articles (09/2015 - 02/2002)|
|10.||Czuczman, Myron S: 33 articles (04/2015 - 02/2002)|
|1.||rituximab (Mabthera)FDA Link
04/01/2012 - "AIMS Rituximab has dramatically improved the survival of patients with non-Hodgkin's lymphoma (NHL). "
04/01/2006 - "CHOP combined with rituximab (R-CHOP) is regarded as one of the most effective treatments for indolent B-cell non-Hodgkin lymphoma (B-NHL), however, its optimal combination schedule remains unknown. "
12/01/2004 - "The anti-CD20 antibody rituximab is useful in the treatment of certain B-cell malignancies, most notably non-Hodgkin's lymphoma. "
04/01/2004 - "Most experience is available for anti-CD20 (rituximab) which led to a significant improvement of the outcome in B-cell non-Hodgkin's lymphoma (NHL). "
02/01/2003 - "In summary, rituximab appears highly active as first-line single-agent therapy for indolent non-Hodgkin's lymphoma and responses may be improved with maintenance courses of rituximab. "
|2.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
02/01/1991 - "A study has been in progress since June 1985 to evaluate the use of myeloablative therapy (cyclophosphamide [60 mg/kg x 2] and total body irradiation [200 cGy x 6]) followed by reinfusion of autologous bone marrow in patients in second or subsequent remission of B-cell non-Hodgkin's lymphoma. "
01/15/2004 - "Inadequate clearance of cyclophosphamide to active metabolites is associated with increased risk of recurrence of B-cell non-Hodgkin's lymphoma in children. "
01/15/2004 - "The median clearance of cyclophosphamide in patients who remain free of B-cell non-Hodgkin's lymphoma was 3.7 liter/h/m(2) (range, 2.3-5.0 liter/h/m(2)), compared with 2.2 (range, 1.5-2.5 liter/h/m(2)) in those with disease recurrence. "
01/01/1967 - "[Remission of the generalized radiologic pattern of reticulosarcoma of the skeletal system in the course of treatment with endoxan]."
10/01/1966 - "Efficacy of cyclophosphamide in the management of reticulum cell sarcoma."
|3.||Doxorubicin (Adriamycin)FDA LinkGeneric
07/01/1999 - "The results suggest that doxorubicin cannot be recommended as a single agent for treatment of feline lymphosarcoma because of the rather poor remission rate achieved."
08/01/1986 - "Further studies investigating the efficacy of weekly versus conventional scheduling of doxorubicin are warranted in non-Hodgkin's lymphoma, particularly in light of published evidence that weekly doxorubicin administration is also less cardiotoxic than treatment given every 3 weeks."
06/01/2008 - "We evaluated the toxicity and efficacy of nonpegylated liposomal doxorubicin (Myocet) when substituted for conventional doxorubicin in the CHOP-21 regimen in the treatment of frail elderly patients with aggressive non-Hodgkin lymphoma. "
07/01/1999 - "To determine the efficacy of doxorubicin when used alone in inducing remission in cats with lymphosarcoma. "
07/01/1999 - "Efficacy of doxorubicin as an induction agent for cats with lymphosarcoma."
|4.||Vincristine (Oncovin)FDA LinkGeneric
06/15/1984 - "These data suggest the possibility of enhancing the therapeutic efficacy of vincristine in the treatment of non-Hodgkin's lymphoma by use of an infusion technique."
01/01/1990 - "Phase I and II trials of vincristine infusion have demonstrated the safety and efficacy of this approach in the treatment of patients with refractory non-Hodgkin's lymphoma. "
03/01/2004 - "A randomized trial in patients treated with vincristine for Hodgkin's or non-Hodgkin's lymphoma."
01/01/1989 - "Vincristine (VCR) given by infusion has been shown in a phase II trial to be active in some cases of non-Hodgkin's lymphoma despite prior exposure to bolus VCR. "
12/01/2010 - "Immunological involvement of peripheral nervous system in non-Hodgkin lymphoma (NHL) is very rare and it may be difficult to differentiate it from vincristine-induced neuropathy. "
|5.||Prednisone (Sone)FDA LinkGeneric
01/01/1959 - "[A case of reticulosarcoma treated with large doses of prednisone]."
02/01/1957 - "[Reticulosarcoma of the scapula; treatment with delta cortisone]."
09/01/2013 - "Treatments for high-, intermediate-, and low-grade lymphomas were divided into 4 groups: absence of treatment, chemotherapy with or without hydroxydaunorubicin, and only prednisone. "
09/01/2005 - "This therapy was modified from CHOP in the treatment of patients with non-Hodgkin's lymphoma: CTX 600 mg/m(2), VCR 1.1 mg/m(2) were administrated by intravenous infusion every 2-4 weeks, prednisone was given orally at 1 mg.kg(-1).d(-1) for seven days after each infusion. "
04/15/1998 - "The 8 patients with multicentric disease were further subdivided according to initial treatment: Three patients who received combination chemotherapy are currently alive and free of disease; 2 patients treated with prednisone are alive but have needed intermittent maintenance therapy for disease reactivations; and 2 patients treated with surgery only have died, 1 of infectious complications and 1 of non-Hodgkin lymphoma. "
|6.||Etoposide (VP 16)FDA LinkGeneric
09/07/1994 - "Aggressive non-Hodgkin's lymphoma in the elderly: an effective, well-tolerated treatment regimen containing extended-schedule etoposide."
06/01/1996 - "Promising results have been reported for patients with non-Hodgkin's lymphoma (NHL) receiving chronic oral etoposide. "
02/01/2000 - "This study was undertaken to investigate the pharmacokinetics of etoposide for optimizing its oral dosage in elderly patients with non-Hodgkin's lymphoma (NHL) using the fraction of dose absorbed calculated from the data generated from first oral and intravenous doses in the same patient. "
01/01/2014 - "In conclusion, the mobilization yield was significantly influenced by the chemomobilization regimen, and HD VP-16 was a highly effective mobilization regimen in patients with non-Hodgkin lymphoma."
06/01/2010 - "The dephosphorylation of FOXO1 inhibited proliferation of Jurkat cells and Namalwa cells, promoted their apoptosis and sensitized Non-Hodgkin lymphoma cells to etoposide. "
09/01/2007 - "Fludarabine-containing regimens is well tolerated and effective in the treatment of low grade non-Hodgkin's lymphoma."
12/01/1999 - "Fludarabine is effective in chronic lymphocytic leukaemia (CLL) and low-grade non-Hodgkin's lymphoma (NHL). "
08/01/2002 - "Phase II study of fludarabine combined with interferon-alpha-2a followed by maintenance therapy with interferon-alpha-2a in patients with low-grade non-hodgkin's lymphoma."
06/01/1996 - "The aim of the study was to investigate the therapeutic activity of Fludarabine in patients with low-grade non-Hodgkin's lymphoma (LG-NHL) no longer responding to standard treatment. "
06/01/1996 - "Fludarabine: a phase II trial in patients with previously treated low-grade lymphoma."
|8.||Granulocyte Colony-Stimulating Factor (G-CSF)IBA
07/01/2004 - "In the treatment of advanced aggressive non-Hodgkin's lymphoma (NHL), we investigated the efficacy of granulocyte colony-stimulating factor (G-CSF)-supported, dose-intensified strategies. "
12/01/1995 - "Efficacy of delayed granulocyte colony-stimulating factor after full dose CHOP therapy in non-Hodgkin's lymphoma: a pilot study for a leukocyte count oriented regimen."
09/01/2011 - "This combination has also been found to be superior to G-CSF alone in Phase III studies in myeloma and non-Hodgkin lymphoma patients as the first-line mobilization. "
08/01/2011 - "For a PET/CT study, an interval of 10 days after G-CSF administration is recommended to minimize the influence of G-CSF on the bone marrow when evaluating treatment response in patients with non-Hodgkin's lymphoma."
08/01/2011 - "To clarify the change in the fluorodeoxyglucose (FDG) uptake by the bone marrow over time after administration of granulocyte colony-stimulating factor (G-CSF), we evaluated the correlation between the interval from the last day of administration of G-CSF to positron emission tomography/computed tomography (PET/CT) study and spinal bone marrow accumulation in patients with non-Hodgkin's lymphoma. "
|9.||Cytarabine (Cytosar-U)FDA LinkGeneric
01/01/1992 - "The results suggest that the cytarabine dose that is expected to be therapeutic for vitreoretinal non-Hodgkin's lymphoma (about 90 micrograms given in three doses of 30 micrograms) is non-toxic for ocular structures."
07/01/2011 - "Intrathecal (IT) liposomal cytarabine, a formulation with prolonged half-life, has been shown to be safe and effective in the treatment of meningeal disease in patients with high-grade lymphoma. "
03/01/1987 - "Therefore, we began a phase II trial of the combination of HU and ara-C to determine the efficacy and toxicity of this combination in treatment of patients with refractory non-Hodgkin's lymphoma. "
07/01/2011 - "Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma."
02/01/2011 - "Liposomal cytarabine has a prolonged half-life and, given intrathecally, has produced high response rates in patients with central nervous system relapse of non-Hodgkin's lymphoma. "
08/01/2002 - "Bendamustine is effective in relapsed or refractory aggressive non-Hodgkin's lymphoma."
05/01/2014 - "Bendamustine-based therapy as first-line treatment for non-Hodgkin lymphoma."
05/01/2014 - "The results of randomised and observational studies with bendamustine as front-line therapy in non-Hodgkin lymphoma (NHL) with emphasis on efficacy and toxicity are presented. "
03/01/2012 - "In indolent non-Hodgkin's lymphoma, assessment of bendamustine is mainly based on a single uncontrolled trial. "
11/14/2015 - "[Progress of bendamustine in the treatment of B cell non-Hodgkin lymphoma]."
|1.||Drug Therapy (Chemotherapy)
10/01/2010 - "Although intensive multi-agent chemotherapy has made non-Hodgkin's lymphoma one of the most curable malignancies in children and young adults, there is room for improvement in treatment, particularly for those with advanced-stage disease and those who relapse after conventional therapy. "
01/01/2008 - "Gastric lymphosarcomas are sensitive to chemotherapy, thereby PCT only is effective in most patients. "
11/01/2001 - "A brief course of chemotherapy followed by radiation therapy was considered the best treatment for localized high-grade Non-Hodgkin's Lymphoma (NHL). "
11/01/1998 - "The use of intensive chemotherapy and incorporation of prophylactic treatment of the central nervous system have dramatically improved the outcome of children with non-Hodgkin's lymphoma (NHL). "
04/26/1990 - "We conclude that most children with localized non-Hodgkin's lymphoma can be cured by a chemotherapy regimen of reduced intensity and duration. "
10/01/2003 - "In a group of 35 patients with relapsed and/or chemo-resistant non-Hodgkin's lymphoma (NHL), low-dose total body irradiation (LTBI) (+involved-field radiotherapy to bulky sites) achieved a complete remission rate of 29%, 2-years progression-free survival of 32% and a median progression-free survival of 12 months. "
02/01/1991 - "Further chemotherapeutic treatment, combined with radiotherapy, led to a complete remission of the non-Hodgkin's lymphoma; the remission lasted for 6 months. "
01/01/2009 - "The aim and objective of the study is to compare the efficacy of conditioning regimens with or without high-dose radiotherapy for treating aggressive non-Hodgkin's lymphoma (NHL). "
05/01/2004 - "Twelve weeks of VACOP-B treatment with or without radiotherapy was shown to be effective and feasible for stage II. These observations need to be confirmed by a phase III study comparing first and third generation protocols in stage I-II aggressive non-Hodgkin's lymphoma."
11/01/2004 - "Biweekly THP-COP plus radiotherapy is feasible and effective for Stage I-II low-risk non-Hodgkin's lymphoma."
|3.||Stem Cell Transplantation
10/01/2002 - "Autologous stem cell transplantation as upfront first line therapy for patients with aggressive non-Hodgkin s lymphoma does not contribute to a better outcome, most certainly not if it concerns patients with a favorable risk profile. "
02/01/1998 - "The aim of the study was to retrospectively evaluate the outcome of patients with aggressive non-Hodgkin's lymphoma (NHL), undergoing autologous stem cell transplantation (ASCT) in first complete (CR) or partial (PR) remission, according to the age-adjusted International Prognostic Index (IPI). "
06/01/2005 - "Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40."
03/01/2005 - "Thus, large randomized trials are required to fully define the role of autologous stem cell transplantation in first-line treatment for high-risk non-Hodgkin lymphoma. "
12/01/2014 - "High-dose therapy and autologous stem cell transplantation (HDT-ASCT) can offer potential long-term remission or cure in patients with non-Hodgkin lymphoma (NHL). "
|4.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
10/01/2002 - "To evaluate the effect on survival of negative immunomagnetic purging in aggressive B-cell non-Hodgkin's lymphoma (NHL), 20 patients retrospectively staged according to the age-adjusted International Prognostic Index as high-intermediate (11 patients) or high-risk (9 patients) received autologous bone marrow transplantation (ABMT) in first complete remission (CR1). "
10/01/2002 - "Autologous bone marrow transplantation with negative immunomagnetic purging for aggressive B-cell non-Hodgkin's lymphoma in first complete remission."
09/01/1994 - "Autologous bone marrow transplantation in poor-risk high-grade non-Hodgkin's lymphoma in first complete remission. "
08/01/1994 - "Autologous bone marrow transplantation is effective in patients with relapsed non-Hodgkin lymphoma and should be considered an important therapeutic option."
01/01/1994 - "One hundred and eighteen patients presenting with high-grade non-Hodgkin's lymphoma, undergoing autologous bone marrow transplantation (ABMT) in first complete remission (CR), have been reported to the European Group for Bone Marrow Transplantation (EBMT). "
|5.||Combination Drug Therapy (Combination Chemotherapy)
03/01/2002 - "The use of effective combination chemotherapy for all stages and subtypes of non-Hodgkin"s lymphoma (NHL) in children has resulted in a striking improvement in cure rates. "
01/01/2002 - "MTX-based combination chemotherapy has yielded the best results to date but the prognosis of patients with PCNSL remains significantly worse than comparable patients with systemic non-Hodgkin's lymphoma (NHL). "
10/01/1991 - "Treatment of low-grade lymphomas with combination chemotherapy results in complete remission rates varying from 25% to 70%. "
12/01/1985 - "[Patterns of relapse in non-Hodgkin's lymphoma after complete remission induced by combination chemotherapy]."
02/01/1975 - "An analysis of patterns of relapse from complete remission in patients with non-Hodgkin's lymphoma treated with combination chemotherapy has demonstrated differences between histologic subgroups. "